- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04013984
Acupuncture for Treatment of Patients With Poor Ovarian Response
The Effect of Acupuncture on in Vitro Fertilization/ Intracytoplasmic Sperm Injection Embryo Transfer (IVF/ICSI-ET) Outcomes in Patients With Poor Ovarian Response Diagnosis: A Randomized Controlled Trial
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Poor ovarian response (POR) is a challenging issue in assisted reproduction treatment. Different controlled ovarian hyperstimulation protocols and strategies have been used in this group of women to improve reproductive outcome, but the success rate still remains low. The aim of this study was to determine the effect of acupuncture during ovulation induction on the results of IVF / ICSI cycles in patients with POR diagnosis. The study was approved by the institutional review board. Written, informed consent will be obtained from each participant. Infertile women with a diagnosis of POR, who undergoing the IVF / ICSI cycle are assigned to four groups by stratified randomization method according to ovarian stimulation protocol. Before the starting the treatment cycle, patients will be randomized with sealed randomization envelopes. The random allocation is concealed from the physician performing the IVF/ICSI treatment cycle. All patients will receive acupuncture by the same physician (Dr.Salimi). In experimental groups (A), acupuncture will be applied for 30 minutes in each session and will be started from the month prior to onset of ovarian stimulation (two sessions of a weekly), and during the ovarian stimulation cycle (two sessions of a weekly), totally 7 acupuncture sessions will be carried out. Acupuncture will be performed using sterile needle on specific points (CV 3 (Zhongji), CV 4 (Guanyuan), ST 25 (Tianshu), ST 28 (Shuidao), ST 29 (Guilai), and LR 3 (Taichong), BL 23 (Shenshu), BL 32 (Ciliao), GV 20 (Baihui), GV 24 (Shenting), GB 13 (Benshen), ST 36 (Zusanli), SP 6 Sanyinjiao), SP 8, SP 10 and KI 3 (Taixi)). The needles were inserted to a depth of 15-30 mm, depending on the region of the body. No sham acupuncture is considered in the control group for ethical and practical reasons. There is no intervention in the control groups (B).
Controlled ovarian stimulation for patients in both groups will be performed according the long stopped protocol. GnRH agonist (Buserelin, 0.5 mg), beginning on day 18 of the previous cycle will be used for down regulation and then will be stopped on the starting ovarian stimulation. Ovarian stimulation will be done with recombinant FSH and hMG (225 IU recombinant FSH (Gonal-F®; Serono Laboratories Ltd., Geneva, Switzerland) and 75 IU hMG (Menopur®; Ferring). The doses of gonadotropins were adjusted as ovarian response in the ultrasound monitoring. Ovulation was triggered with hCG (10,000 IU) when at least three follicles have a diameter of 18 mm with an adequate serum E2 concentration.
In both group, transvaginal oocyte retrieval will be performed under ultrasound guidance 32-34 hours after hCG administration. Intracytoplasmic sperm injection will be performed for all metaphase II oocytes. Embryo transfer will be done under ultrasound guidance on day 3 for all patients.
Primary consequences in this study are the total number of retrieved and MII oocytes and quality of the obtained embryos. Secondary outcomes are implantation and clinical pregnancy rates that confirmed by vaginal ultrasound (pregnancy sac and embryonic heart activity). The IVF/ICSI outcomes are compared in four groups. Data collection will be performed by using questionnaire to be filled as per the available records and laboratory results. Data analysis will be done through descriptive and perceptive statistical methods by using SPSS software version 20 for windows.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Tehran, Iran, Islamic Republic of, 16635-148
- Royan Institute
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
1- Diagnosis of Poor ovarian response (POR), according to POSSEIDON group criteria (Group 3) Young patients (<35 years) with poor ovarian reserve prestimulation parameters (AFC <5, AMH<1.2 ng/mL).
Exclusion Criteria:
- Premature ovarian failure diagnosis.
- Endometriosis grade III or IV.
- Any contraindications to ovarian stimulation treatment.
- Uterine infertility factor.
- Previous history of ovarian surgery.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Accupuncture
Acupuncture twice a week during the preceding cycle and the ovarian stimulation by "GnRH agonist stopped protocol".
|
In experimental groups (A), acupuncture will be applied for 30 minutes in each session and will be started from the month prior to onset of ovarian stimulation (two sessions of a weekly), and during the ovarian stimulation cycle (two sessions of a weekly), totally 7 acupuncture sessions will be carried out.
Acupuncture will be performed using sterile needle on specific points (CV 3 (Zhongji), CV 4 (Guanyuan), ST 25 (Tianshu), ST 28 (Shuidao), ST 29 (Guilai), and LR 3 (Taichong), BL 23 (Shenshu), BL 32 (Ciliao), GV 20 (Baihui), GV 24 (Shenting), GB 13 (Benshen), ST 36 (Zusanli), SP 6 Sanyinjiao), SP 8, SP 10 and KI 3 (Taixi)).
The needles were inserted to a depth of 15-30 mm, depending on the region of the body.
No sham acupuncture is considered in the control group for ethical and practical reasons
|
No Intervention: Non-accupuncture
Ovarian stimulation by" GnRH agonist stopped protocol" without intervention.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Total number of retrieved oocytes
Time Frame: Day of oocyte pick-up, 34-36 hours after hCG administration (approximately Stimulation Day 10)
|
At the point of ovum pick-up, we can count total number of retrieved oocytes.
Therefore, in one hour after ovum pick-up, outcome measurement will be possible.
|
Day of oocyte pick-up, 34-36 hours after hCG administration (approximately Stimulation Day 10)
|
Oocyte maturity
Time Frame: Day of oocyte pick-up, 34-36 hours after hCG administration (approximately Stimulation Day 10)
|
At the point of ovum pick-up, we can count how many mature or immature oocytes were retrieved.
Therefore, in one hour after ovum pick-up, outcome measurement will be possible.
|
Day of oocyte pick-up, 34-36 hours after hCG administration (approximately Stimulation Day 10)
|
Quality of obtained embryos
Time Frame: 3 days after IVF/ICSI procedure
|
Embryo grade assessed under invert microscope 3 days after intracytoplasmic sperm injection procedure [ Time Frame: 3 days after intracytoplasmic sperm injection procedure ] Embryo grade assessed under invert microscope 3 days after intracytoplasmic sperm injection procedure.The quality of embryos was graded from 1 to 3 under inverted microscope 3 days after intracytoplasmic sperm injection procedure.
Embryos with even-sized blastomers and/or <5% fragments were classified as Grade 1 (good quality).
Grade 2 embryos (moderate quality) had blastomeres with slightly-moderate size differences and/or 5-50% fragments.
Grade 3 embryos (poor quality) had markedly different-sized blastomers and/or >50% fragments.
|
3 days after IVF/ICSI procedure
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Implantation rate
Time Frame: 4 weeks after embryo transfer
|
The ratio of total number of observed gestational sacs to total number of transferred embryos.
|
4 weeks after embryo transfer
|
Clinical pregnancy rate
Time Frame: 4-6 weeks after embryo transfer
|
The observation of gestational sac with heart beat by using trans-vaginal ulterasound
|
4-6 weeks after embryo transfer
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- POR-accupuncure
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Poor Ovarian Response
-
Barzilai Medical CenterRecruitingPoor Ovarian Response | Ovarian InsufficiencyIsrael
-
Nanjing UniversityRecruiting
-
ShangHai Ji Ai Genetics & IVF InstituteCompleted
-
Al Baraka Fertility HospitalUnknown
-
Shaanxi Hospital of Traditional Chinese MedicineNorthwest Women's and Children's Hospital, Xi'an, ShaanxiUnknown
-
GeneScience Pharmaceuticals Co., Ltd.Peking University People's Hospital; Peking University Third HospitalUnknown
-
Shi YunXiyuan Hospital, China Academy of Traditional Chinese MedicineRecruiting
-
Mỹ Đức HospitalCompletedPoor Ovarian ResponseVietnam
-
Sixth Affiliated Hospital, Sun Yat-sen UniversityRecruiting
-
Sheba Medical CenterUnknownWomen With Poor Ovarian ResponseIsrael
Clinical Trials on Accupuncture
-
Shin Kong Wu Ho-Su Memorial HospitalCompletedDermatologic DiseaseTaiwan
-
Kaiser PermanenteNational Center for Complementary and Integrative Health (NCCIH)Completed
-
University of New MexicoCompletedBreast CancerUnited States
-
University of Social Welfare and Rehabilitation...Completed
-
University of Social Welfare and Rehabilitation...CompletedPatellofemoral Pain SyndromeIran, Islamic Republic of